Publication2023
Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants
- Good Health and Well-being
- Partnerships for the Goals
- Empowered Indians
The record
- Type
- Publication
- Date
- 1 January 2023
- Level
- International — held abroad
- Journal
- Human Vaccines and Immunotherapeutics
- Volume
- 19
- Issue
- 3
- Published
- 1 January 2023
- DOI
- 10.1080/21645515.2023.2278346
- Scopus ID
- 85177038426
- ISSN
- 21645515
- Authors
- 23
- Open access
- Yes
- Citations
- 3
- International co-authorship
- Yes
- Co-author countries
- IN, US
Classification
Every label below carries the reasoning it was assigned on, the confidence band it was assigned in, and what produced it. The rubric is published.
UN Sustainable Development Goals
3.2 End preventable deaths of newborns and children under five years of age
ROTAVAC rotavirus vaccine immunogenicity and lot-to-lot consistency testing in Phase III clinical trials.
- Certain confidence
- The record states the subject matter explicitly. A reader shown only the title and this goal would agree without hesitation. Example: a workshop titled "Renewable Energy and Smart Grid" against SDG 7.
- Judged
- Judged against the published classification rubric, under the rubric and prompt versions recorded with the run that produced it.
- Produced by
- claude-haiku-4-5-20251001, under kortex-publication-v1
17.6 Enhance North-South, South-South and triangular cooperation on science, technology and innovation, and knowledge sharing
Structural signal: co-authorship outside India.
- High confidence
- The subject matter is a strong and direct inference from the record type, the funding or organising body, or the programme context, even where the title alone is thin. Example: an ICMR-funded project against SDG 3, on the strength of the agency.
- Rule-derived
- Emitted by a deterministic rule from structural signals rather than judged from the record’s text. The rule carries a version, so rule-derived and judged labels stay separable.
- Produced by
- sdg17-structural-v1, under kortex-publication-v1
Viksit Bharat @2047
vb-1 Empowered Indians
Derived through the seeded SDG-to-Viksit-Bharat crosswalk from the primary SDG 3 label. ROTAVAC rotavirus vaccine immunogenicity and lot-to-lot consistency testing in Phase III clinical trials.
- Produced by
- claude-haiku-4-5-20251001, under kortex-publication-v1
Each label above carries the instrument and the version that produced it. How each classification is reached.
Evidence
Kortex hosts no documents. Evidence is an outbound link to the authority that holds it.
No outbound evidence link is recorded for this activity. The record below states which source it came from and when it was last read.
Provenance
Which source system this record came from, how many source rows were resolved into it, and when each was last read.
- Source rows resolved into this record
- 1
Each record carries the date Kortex last read it from its source system. That is a freshness date and not a verification: Kortex records what its sources say and when it read them, and it does not check those statements against any external authority. No claim on this site is described as verified, because none is.
Citing this record
This URL is stable. A record’s permalink is frozen when it is published and is not regenerated if its title is later corrected.
KIIT Deemed to be University. “Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants”. Kortex.